299 related articles for article (PubMed ID: 38674018)
1. Exploring Current Molecular Targets in the Treatment of Neovascular Age-Related Macular Degeneration toward the Perspective of Long-Term Agents.
Fragiotta S; Bassis L; Abdolrahimzadeh B; Marino A; Sepe M; Abdolrahimzadeh S
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674018
[TBL] [Abstract][Full Text] [Related]
2. Current therapeutic approaches in neovascular age-related macular degeneration.
Nguyen DH; Luo J; Zhang K; Zhang M
Discov Med; 2013 Jun; 15(85):343-8. PubMed ID: 23819948
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.
Sunaga T; Maeda M; Saulle R; Ng SM; Sato MT; Hasegawa T; Mason AN; Noma H; Ota E
Cochrane Database Syst Rev; 2024 Jun; 6(6):CD015804. PubMed ID: 38829176
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
7. Current status of vascular endothelial growth factor inhibition in age-related macular degeneration.
Mousa SA; Mousa SS
BioDrugs; 2010 Jun; 24(3):183-94. PubMed ID: 20210371
[TBL] [Abstract][Full Text] [Related]
8. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
Ng EW; Adamis AP
Can J Ophthalmol; 2005 Jun; 40(3):352-68. PubMed ID: 15947805
[TBL] [Abstract][Full Text] [Related]
9. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
[TBL] [Abstract][Full Text] [Related]
10. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
Nguyen TT; Guymer R
Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
[TBL] [Abstract][Full Text] [Related]
11. VEGF inhibitors for the treatment of neovascular age-related macular degeneration.
Barakat MR; Kaiser PK
Expert Opin Investig Drugs; 2009 May; 18(5):637-46. PubMed ID: 19388880
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
Mitchell P
Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
[TBL] [Abstract][Full Text] [Related]
13. [Vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration].
Dyakov IN; Zyryanov SK
Vestn Oftalmol; 2017; 133(2):125-129. PubMed ID: 28524152
[TBL] [Abstract][Full Text] [Related]
14. Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis.
Luu KT; Seal J; Green M; Winskill C; Attar M
J Clin Pharmacol; 2022 May; 62(5):594-608. PubMed ID: 34783362
[TBL] [Abstract][Full Text] [Related]
15. Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
Yazdi MH; Faramarzi MA; Nikfar S; Falavarjani KG; Abdollahi M
Expert Opin Biol Ther; 2015; 15(9):1349-58. PubMed ID: 26076760
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
Liberski S; Wichrowska M; Kocięcki J
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012690
[TBL] [Abstract][Full Text] [Related]
17. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
Lu X; Sun X
Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept for neovascular age-related macular degeneration.
Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
[TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.
Nguyen CL; Oh LJ; Wong E; Wei J; Chilov M
BMC Ophthalmol; 2018 May; 18(1):130. PubMed ID: 29843663
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy.
Nair AA; Finn AP; Sternberg P
Drug Des Devel Ther; 2022; 16():3395-3400. PubMed ID: 36199631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
